Results 171 to 180 of about 35,812 (218)

Multi-omics analysis constructs a novel neuroendocrine prostate cancer classifier and classification system. [PDF]

Sci Rep
Shen J, Lu L, Chen Z, Guo W, Wang S, Liu Z, Gong X, Qi Y, Jin R, Zhang C.   +9 more
europepmc   +1 more source

New insights into markers for distinguishing neuroendocrine prostate cancer: evidence from single-cell analysis. [PDF]

Front Immunol
Luo H, Li B, Zhang M, Wang H, Hao Z, Ge Q, Liang C.   +6 more
europepmc   +1 more source

A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma. [PDF]

Cancer Med
Fukui T, Okasho K, Okuno Y, Fujiwara M, Hikami K, Fukunaga A, Sunada T, Kita Y, Sumiyoshi T, Goto T, Saito R, Ogawa O, Kobayashi T, Akamatsu S.   +13 more
europepmc   +1 more source

Identification of the specific characteristics of neuroendocrine prostate cancer: Immune status, hub genes and treatment. [PDF]

Transl Oncol
Wang J, Wang Y, Zhou H, Yu G, Xu H, Gao D, Li M, Wang Y, Xu B.   +8 more
europepmc   +1 more source

RB1 and p53 are diagnostic markers for treatment-related neuroendocrine prostate cancer: a clinical and pathological analysis of 23 cases. [PDF]

Am J Clin Exp Urol
Zhang Y, Shi M, Zhang Y, Wang J, Zhang H, Ren G.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immunogenomic Landscape of Neuroendocrine Prostate Cancer

Clinical Cancer Research, 2023
Abstract Purpose: Patients with neuroendocrine prostate cancer (NEPC) are often managed with immunotherapy regimens extrapolated from small-cell lung cancer (SCLC). We sought to evaluate the tumor immune landscape of NEPC compared with other prostate cancer types and SCLC.
Bhavneet Bhinder, Alison Ferguson, Michael Sigouros, Manik Uppal, Ahmed G. Elsaeed, Rohan Bareja, Hussein Alnajar, Kenneth Wha Eng, Vincenza Conteduca, Andrea Sboner, Juan Miguel Mosquera, Olivier Elemento, Himisha Beltran   +12 more
openaire   +3 more sources

Prostate Cancer and Neuroendocrine Differentiation

International Urology and Nephrology, 1999
A retrospective study was conducted in 41 patients with adenocarcinoma of the prostate to investigate the correlation between pathological stage, Gleason score and neuroendocrine differentiation in order to evaluate the prognostic significance of neuroendocrine differentiation. Patients' ages ranged from 50 to 84 (mean 69.1) years. Clinical staging was
ÇELİK, BÜLENT, Karaoǧlan, Ü., Ataoǧlu, Ö., Biri, H., Bozkirli, I., TAN, MUSTAFA ÖZGÜR   +5 more
openaire   +3 more sources

Treatment Outcomes in Neuroendocrine Prostate Cancer

Anticancer Research, 2022
Neuroendocrine prostate cancer (NEPC) is rare and has a poor prognosis; its clinical course and treatment outcomes are also unclear. This study investigated the clinical characteristics, clinical course, and treatment outcomes of patients with NEPC.This retrospective study investigated 14 patients histologically diagnosed with NEPC at Kanazawa ...
Hiroaki, Iwamoto, Ryunosuke, Nakagawa, Tomoyuki, Makino, Suguru, Kadomoto, Hiroshi, Yaegashi, Takahiro, Nohara, Kazuyoshi, Shigehara, Kouji, Izumi, Yoshifumi, Kadono, Atsushi, Mizokami   +9 more
openaire   +2 more sources

Neuroendocrine Cells in Prostate Cancer

Critical Reviews in Eukaryotic Gene Expression, 2004
Neuroendocrine (NE) cells are found in prostate tumors, and their incidence is considered a promising prognostic indicator for the development of androgen-independent disease. NE cells are derived from non-NE prostate cancer cells and secrete factors that can act in a paracrine manner to stimulate the survival, growth, motility, and metastatic ...
George P, Amorino, Sarah J, Parsons
openaire   +2 more sources

Neuroendocrine Target Therapies for Prostate Cancer

Urologia Journal, 2011
It is important to determine whether an increase in Chromogranin A levels and neuroendocrine (NE) cell activation are associated with progression towards on hormone-independent prostate-cancer. We proposed a combination of estrogens and somatostatin analogues as therapy of NE activation in hormone-independent prostate cancer. The combined therapy with
SCIARRA, Alessandro, Innocenti M, Ravaziol M, Minisola F, Alfarone A, Cattarino S, Monti S, GENTILE, Vincenzo, DI SILVERIO, Franco   +8 more
openaire   +2 more sources